ERNA vs. MTEM, ABVC, MIRA, GHSI, MBRX, AKTX, ELAB, CMMB, ATHE, and AEZS
Should you be buying Eterna Therapeutics stock or one of its competitors? The main competitors of Eterna Therapeutics include Molecular Templates (MTEM), ABVC BioPharma (ABVC), MIRA Pharmaceuticals (MIRA), Guardion Health Sciences (GHSI), Moleculin Biotech (MBRX), Akari Therapeutics (AKTX), Elevai Labs (ELAB), Chemomab Therapeutics (CMMB), Alterity Therapeutics (ATHE), and Aeterna Zentaris (AEZS). These companies are all part of the "pharmaceutical preparations" industry.
Molecular Templates (NASDAQ:MTEM) and Eterna Therapeutics (NASDAQ:ERNA) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, community ranking, valuation, profitability, risk, earnings, dividends and media sentiment.
Molecular Templates received 342 more outperform votes than Eterna Therapeutics when rated by MarketBeat users.
Molecular Templates has a beta of 1.15, meaning that its share price is 15% more volatile than the S&P 500. Comparatively, Eterna Therapeutics has a beta of 4.31, meaning that its share price is 331% more volatile than the S&P 500.
Eterna Therapeutics has a net margin of 0.00% compared to Eterna Therapeutics' net margin of -14.18%. Molecular Templates' return on equity of -508.73% beat Eterna Therapeutics' return on equity.
95.5% of Molecular Templates shares are owned by institutional investors. Comparatively, 70.6% of Eterna Therapeutics shares are owned by institutional investors. 13.4% of Molecular Templates shares are owned by company insiders. Comparatively, 35.4% of Eterna Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Molecular Templates has higher revenue and earnings than Eterna Therapeutics. Molecular Templates is trading at a lower price-to-earnings ratio than Eterna Therapeutics, indicating that it is currently the more affordable of the two stocks.
In the previous week, Eterna Therapeutics had 1 more articles in the media than Molecular Templates. MarketBeat recorded 3 mentions for Eterna Therapeutics and 2 mentions for Molecular Templates. Eterna Therapeutics' average media sentiment score of 1.44 beat Molecular Templates' score of 0.85 indicating that Molecular Templates is being referred to more favorably in the media.
Summary
Molecular Templates and Eterna Therapeutics tied by winning 7 of the 14 factors compared between the two stocks.
Get Eterna Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for ERNA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ERNA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Eterna Therapeutics Competitors List
Related Companies and Tools
